We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Veeva Systems (VEEV) Inks Deal to Serve Rare Disease Patients
Read MoreHide Full Article
Veeva Systems Inc. (VEEV - Free Report) recently announced a collaboration with ANI Pharmaceuticals, Inc. (ANIP - Free Report) to define and operationalize data-driven commercial strategies for the latter’s new Rare Disease business unit. Veeva Systems’ software, data, and services are being utilized by ANI Pharmaceuticals to create the digital foundation for the launch of the business unit's first commercially available product in the United States.
The latest tie-up, resulting in the growing adoption of Veeva Systems’ applications, is expected to provide a significant boost to the Veeva Commercial Cloud product line of its Life Sciences segment.
Significance of the Adoption
Per ANI Pharmaceuticals’ management, the company needs to be agile, data-driven and efficient to serve rare disease patients having high unmet medical needs. The tie-up with Veeva Systems will likely advance its launch readiness and supply new sales, medical and marketing teams with the required digital tools.
Veeva Systems’ management believes ANI Pharmaceuticals currently has the digital foundation that supports its patient-centric approach to commercialization. This is expected to ultimately leverage data to uncover key patient groups as well as their care providers.
Industry Prospects
Per a report by Marketsandresearch.biz, the global clinical data management system market was estimated to be $1574.8 million in 2021 and is projected to reach $4294.1 million by 2028 at a CAGR of 15.4%. Factors like a surge in clinical trials, a flourishing healthcare industry, and increasing research collaborations and partnerships are expected to drive the market.
Given the market potential, growing adoption of Veeva Systems’ applications is expected to strengthen its position in the global cloud application space.
Notable Developments
This month, Veeva Systems made an announcement about Veeva Vault Study Training — a new application that combines research sites, clinical research organizations and sponsors into a single platform for end-to-end clinical study training.
Also, this month, Veeva Systems announced solid first-quarter fiscal 2023 results, wherein both of its segments performed impressively. The company continued to benefit from its flagship Vault platform and saw continued strength in its Veeva Commercial Cloud.
Price Performance
Shares of Veeva Systems have lost 40.4% in the past year versus the industry’s 65.9% fall and the S&P 500's 11.8% decline.
Image Source: Zacks Investment Research
Zacks Rank & Key Picks
Currently, Veeva Systems carries a Zacks Rank #3 (Hold).
A couple of better-ranked stocks in the broader medical space are AMN Healthcare Services, Inc. (AMN - Free Report) and Omnicell, Inc. (OMCL - Free Report) .
AMN Healthcare, sporting a Zacks Rank #1 (Strong Buy) at present, has an estimated long-term growth rate of 1.1%. AMN’s earnings surpassed the Zacks Consensus Estimate in all the trailing four quarters, the average beat being 15.6%.
AMN Healthcare has gained 7.6% against the industry’s 54.2% fall in the past year.
Omnicell, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 20%. OMCL’s earnings surpassed estimates in three of the trailing four quarters and missed the same in the other, the average beat being 13.4%.
Omnicell has lost 25.2% compared with the industry’s 59.9% fall over the past year.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Shutterstock
Veeva Systems (VEEV) Inks Deal to Serve Rare Disease Patients
Veeva Systems Inc. (VEEV - Free Report) recently announced a collaboration with ANI Pharmaceuticals, Inc. (ANIP - Free Report) to define and operationalize data-driven commercial strategies for the latter’s new Rare Disease business unit. Veeva Systems’ software, data, and services are being utilized by ANI Pharmaceuticals to create the digital foundation for the launch of the business unit's first commercially available product in the United States.
The latest tie-up, resulting in the growing adoption of Veeva Systems’ applications, is expected to provide a significant boost to the Veeva Commercial Cloud product line of its Life Sciences segment.
Significance of the Adoption
Per ANI Pharmaceuticals’ management, the company needs to be agile, data-driven and efficient to serve rare disease patients having high unmet medical needs. The tie-up with Veeva Systems will likely advance its launch readiness and supply new sales, medical and marketing teams with the required digital tools.
Veeva Systems’ management believes ANI Pharmaceuticals currently has the digital foundation that supports its patient-centric approach to commercialization. This is expected to ultimately leverage data to uncover key patient groups as well as their care providers.
Industry Prospects
Per a report by Marketsandresearch.biz, the global clinical data management system market was estimated to be $1574.8 million in 2021 and is projected to reach $4294.1 million by 2028 at a CAGR of 15.4%. Factors like a surge in clinical trials, a flourishing healthcare industry, and increasing research collaborations and partnerships are expected to drive the market.
Given the market potential, growing adoption of Veeva Systems’ applications is expected to strengthen its position in the global cloud application space.
Notable Developments
This month, Veeva Systems made an announcement about Veeva Vault Study Training — a new application that combines research sites, clinical research organizations and sponsors into a single platform for end-to-end clinical study training.
Also, this month, Veeva Systems announced solid first-quarter fiscal 2023 results, wherein both of its segments performed impressively. The company continued to benefit from its flagship Vault platform and saw continued strength in its Veeva Commercial Cloud.
Price Performance
Shares of Veeva Systems have lost 40.4% in the past year versus the industry’s 65.9% fall and the S&P 500's 11.8% decline.
Image Source: Zacks Investment Research
Zacks Rank & Key Picks
Currently, Veeva Systems carries a Zacks Rank #3 (Hold).
A couple of better-ranked stocks in the broader medical space are AMN Healthcare Services, Inc. (AMN - Free Report) and Omnicell, Inc. (OMCL - Free Report) .
AMN Healthcare, sporting a Zacks Rank #1 (Strong Buy) at present, has an estimated long-term growth rate of 1.1%. AMN’s earnings surpassed the Zacks Consensus Estimate in all the trailing four quarters, the average beat being 15.6%.
You can see the complete list of today’s Zacks #1 Rank stocks here.
AMN Healthcare has gained 7.6% against the industry’s 54.2% fall in the past year.
Omnicell, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 20%. OMCL’s earnings surpassed estimates in three of the trailing four quarters and missed the same in the other, the average beat being 13.4%.
Omnicell has lost 25.2% compared with the industry’s 59.9% fall over the past year.